Modeling the gender-specific impact of vaginal microbicides on HIV transmission

Journal of Theoretical Biology

Volumn 288, Issue 1, 2011, Pages 9-20

  Dimitrov, Dobromir T ^a   Boily, Marie Claude ^b   Baggaley, Rebecca F ^b   Masse, Benoit ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Biomedical intervention; Drug resistance; Epidemic; Mathematical model; Prevention

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; UNCLASSIFIED DRUG; VAGINAL MICROBIOCIDE;

DISEASE TRANSMISSION; DRUG RESISTANCE; EPIDEMIC; HUMAN IMMUNODEFICIENCY VIRUS; PARAMETERIZATION; PUBLIC HEALTH; QUANTITATIVE ANALYSIS;

ARTICLE; CIRCUMCISION; CONDOM; DISEASE TRANSMISSION; DRUG EFFICACY; EPIDEMIC; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INFECTION SENSITIVITY; INTERVENTION STUDY; MATHEMATICAL MODEL; MEDICAL RESEARCH; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; SEXUAL BEHAVIOR;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG RESISTANCE, VIRAL; EPIDEMICS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; SEX FACTORS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 80051932199     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.08.001     Document Type: Article

References (26)

1. Abdul Karim Q., Abdul Karim S., Frohlich J., Grobler A., Baxter C., Mansoor L., Kharsany A., Sibeko S., Mlisana K., Omar Z., Gengiah T., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D., Group C.T. Effectiveness and safety of tenofovir gel an antiretroviral microbicide for the prevention of HIV infection in women. Science 2010, 329(5996):1168-1174.
2. Anderson R.M., May R.M., Boily M.C., Garnett G.P., Rowley J.T. The spread of HIV-1 in Africa-sexual contact patterns and the predicted demographic-impact of AIDS. Nature 1991, 352:581-589.
3. Boily M.C., Baggaley R.F., Wang L., Masse B., White R.G., Hayes R.J., Alary M. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infectious Diseases 2009, 9:118-129.
4. Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., Grant R.M. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine 2001, 344:472-480.
5. Diekmann O., Heesterbeek J.A.P., Metz J.A.J. On the definition and the computation of the basic reproduction ratio R0 in models for infectious-diseases in heterogeneous populations. Journal of Mathematical Biology 1990, 28:365-382.
6. Dimitrov D.T., Masse B., Boily M.-C. Who will benefit from a wide-scale introduction of vaginal microbicides in developing countries?. Statistical Communications in Infectious Diseases 2010, 2(1). (Article 4).
7. Ferry B., Carael M., Buve A., Auvert B., Laourou M., Kanhonou L., de Loenzien M., Akam E., Chege J., Kaona F. Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. AIDS 2001, 15:S41-S50.
8. Foss A.M., Vickerman P.T., Heise L., Watts C.H. Shifts in condom use following microbicide introduction: should we be concerned?. AIDS 2003, 17:1227-1237.
9. Foss A.M., Vickerman P.T., Alary M., Watts C.H. How much could a microbicide's sexually transmitted infection efficacy contribute to reducing HIV risk and the level of condom use needed to lower risk? Model estimates. Sexually Transmitted Infections 2009, 85:276-282.
10. Heise L., Philpott S. Predicting the unpredictable real-world impact of ARV-based microbicides. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:E73.
11. Jespers V.A., Van Roey J.M., Beets G.I., Buve A.M. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. JAIDS-Journal of Acquired Immune Deficiency Syndromes 2007, 44:154-158.
12. Kalichman S.C., Simbayi L.C., Cain D., Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. Sexually Transmitted Infections 2009, 85:411-415.
13. Lacey C.J.N., Wright A., Weber J.N., Profy A.T. Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS 2006, 20:1027-1030.
14. Little S.J., Frost S.D.W., Wong J.K., Smith D.M., Pond S.L.K., Ignacio C.C., Parkin N.T., Petropoulos C.J., Richman D.D. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. Journal of Virology 2008, 82:5510-5518.
15. Mayer K.H., Maslankowski L.A., Gai F., El-Sadr W.M., Justman J., Kwiecien A., Masse B., Eshleman S.H., Hendrix C., Morrow K., Rooney J.F., Soto-Torres L. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006, 20:543-551.
16. McCormack S., Jespers V., Low-Beer N., Gabe R., Kaganson N., Chapman A., Nunn A., Lacey C., Van Damme L. A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers. Sexually Transmitted Diseases 2005, 32:765-770.
17. Morgan D., Mahe C., Mayanja B., Okongo J.M., Lubega R., Whitworth J.A.G. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. AIDS 2002, 16:597-603.
18. Pao D., Andrady U., Clarke J., Dean G., Drake S., Fisher M., Green T., Kumar S., Murphy M., Tang A., Taylor S., White D., Underhill G., Pillay D., Cane P. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. JAIDS-Journal of Acquired Immune Deficiency Syndromes 2004, 37:1570-1573.
19. Porter K., Zaba B. The empirical evidence for the impact of HIV on adult mortality in the developing world: data from serological studies. AIDS 2004, 18:S9-S17.
20. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand. New England Journal of Medicine 2009, 361:2209-2220.
21. Smith R.J., Bodine E.N., Wilson D.P., Blower S.M. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 2005, 19:413-421.
22. UNAIDS/WHO, AIDS epidemic update, 2009. UNAIDS/World Health Organization, Geneva November. http://data.unaids.org/pub/Report/2009/jc1700_epi_update_2009_en.pdf.
23. Vickerman P., Watts C., Delany S., Alary M., Rees H., Heise L. The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sexually Transmitted Diseases 2006, 33:397-405.
24. Vickerman P.D., Foss A.P., Watts C.P. Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials. JAIDS-Journal of Acquired Immune Deficiency Syndromes 2008, 48(4):460-467.
25. Wawer M.J., Gray R.H., Sewankambo N.K., Serwadda D., Li X.B., Laeyendecker O., Kiwanuka N., Kigozi G., Kiddugavu M., Lutalo T., Nalugoda F., Wabwire-Mangen F., Meehan M.P., Quinn T.C. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. Journal of Infectious Diseases 2005, 191:1403-1409.
26. Wilson D.P., Coplan P.M., Wainberg M.A., Blower S.M. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9835-9840.